Statin Therapy: Yes. Aspirin: No.
In this 70-year-old woman with <50% coronary plaque on CT angiography, you should initiate statin therapy but NOT aspirin for primary prevention. The presence of any atherosclerotic plaque—even non-obstructive—warrants aggressive lipid management, while aspirin lacks net benefit in primary prevention and carries bleeding risk in this age group.
Statin Recommendation
Start a moderate-to-high intensity statin immediately based on the detection of coronary atherosclerosis 1, 2. The 2019 ACC/AHA guidelines explicitly state that statin therapy is first-line treatment for primary prevention in patients determined to be at sufficient ASCVD risk after clinician-patient discussion 1. At age 70 with documented plaque, she clearly meets this threshold.
Supporting Evidence for Statins
Age-specific data strongly supports statin use in this age group. Meta-analyses demonstrate that in patients 65-70 years old, statins reduce composite cardiovascular endpoints by 49%, and even in those ≥70 years, risk reduction remains substantial at 26% 2
Non-obstructive plaque matters. Multiple studies show that patients with non-obstructive CAD (<50% stenosis) who receive statins demonstrate:
The plaque itself changes risk stratification. Even <50% stenosis represents established atherosclerotic disease, not just risk factors. This moves the patient from primary prevention based on risk scores to treatment of documented disease 6, 5
Practical Statin Approach
Start with atorvastatin 20-40 mg or rosuvastatin 10-20 mg daily. Target LDL cholesterol <70 mg/dL given documented atherosclerosis. Recheck lipids in 4-6 weeks and titrate accordingly.
Aspirin Recommendation
Do NOT start aspirin in this patient 1. This is a critical point where guidelines have evolved significantly.
Why No Aspirin
The 2019 ACC/AHA guidelines explicitly state: "Aspirin should be used infrequently in the routine primary prevention of ASCVD because of lack of net benefit" 1. This is a Class III recommendation (harm may exceed benefit)
Age increases bleeding risk substantially. The FDA label warns that bleeding risk is higher in patients ≥60 years old 7. At age 70, this patient faces significant bleeding risk that likely outweighs any cardiovascular benefit
Recent high-quality evidence shows no benefit in asymptomatic patients with coronary stenosis. A 2025 propensity-matched study of 636 individuals with incidentally diagnosed coronary stenosis found:
Exception to Consider
The only scenario where aspirin might be considered is if she has additional high-risk features such as:
- Lipoprotein(a) >50 mg/dL (some evidence suggests ~50% risk reduction with aspirin in this specific subgroup) 9
- Multiple high-risk plaque features on CCTA (low-attenuation plaque, positive remodeling, spotty calcification)
- Very low bleeding risk (no history of GI bleeding, not on anticoagulation, no significant fall risk)
Even then, this requires careful shared decision-making weighing her specific bleeding versus thrombotic risk.
Risk Factor Management Beyond Medications
While initiating the statin, ensure comprehensive risk factor control:
- Blood pressure target <130/80 mmHg 1
- Lifestyle modifications: Mediterranean diet, 150 minutes/week moderate exercise 1
- Smoking cessation if applicable 1
- Diabetes management if present, with consideration of SGLT2 inhibitor or GLP-1 agonist for additional cardiovascular benefit 1
Common Pitfalls to Avoid
Don't dismiss non-obstructive plaque as insignificant. <50% stenosis still represents atherosclerotic disease requiring treatment 3, 6
Don't reflexively start aspirin because plaque is present. The bleeding risk in elderly patients outweighs benefit in primary prevention 1, 8
Don't use outdated risk calculators alone. The CT angiography finding supersedes risk score calculations—she has documented disease 6
Don't undertreate lipids. Target LDL <70 mg/dL given atherosclerosis presence, not the more lenient primary prevention targets 5